Envista Holdings Corp.

NVST

NYSE; healthcare; SIC 3843, Dental Equipment & Supplies; CIK 0001757073

B/C

on the B/C boundary of 370 graded peers in healthcare

rank 155 of 370; percentile 41.7; sampling error 2.5 points; lower is stronger

A B C D E

B/C, the elk



Scoreboard	
Profitability	C percentile 51.3
Solvency	C percentile 51.6
Growth and financing	B percentile 34.9
Reliability	0.94 AUC filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over $2.67B assets total assets $5.7B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: distress
Inputs computable	11 of 14
Graded from	filings received through Feb 12, 2026 255 days before the rescan; latest periodic filing 10-Q received Aug 5, 2026
Last close	$23.59 2026-10-23; market equity $3.8B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 12, 2026

-Materials," our manufacturing and other operations employ a wide variety of components, raw materials and other commodities, including metallic-based components, electronic components, chemicals, and plastics. Prices for and availability of these components, raw materials and other commodities have fluctuated significantly in the past. Any sustained interruption in the supply of these items, including as a result of shipping risks, such as container shortages, blocked shipping lanes, and port backlogs, could adversely affect our business.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 51.3						
Gross profitability	26.2%	32.3%		55.0	368	2025-12-31
Return on invested capital	1.7%	9.3%		69.9	74	2025-12-31
Accruals ratio	(4.1%)	(6.6%)		65.0	807	2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin stability, five years	1.1 pts	2.8 pts	15.4	242	2025-12-31
Solvency, sleeve percentile 51.6					
Twelve-month failure probability	not computable	0.07%			
liabilities and a nearby cover-page share count are required at 2026-07-03					
Altman Z double-prime	not computable	(0.33)			
one or more required annual facts are missing					
Net debt to EBITDA	0.71x	1.82x	36.5	75	2025-12-31
Interest coverage	not computable	(4.51x)			
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31					
Current ratio	2.38x	2.94x	66.6	834	2025-12-31
Growth and financing, sleeve percentile 34.9					
Revenue growth, three-year compound	1.9%	10.1%	67.0	413	2025-12-31
Free cash flow growth, three-year compound	29.1%	10.9%	33.7	96	2025-12-31
Reinvestment rate	337.9%	37.1%	7.8	104	2025-12-31
Asset growth, three years	(4.8%)	2.1%	62.1	700	2025-12-31
Net share issuance, one year	(4.8%)	2.5%	3.8	636	2026-02-06

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
150	ImmunityBio, Inc. (IBRX)	40.4	B/C	short runway
151	Celldex Therapeutics, Inc. (CLDX)	40.7	B/C	short runway
152	Myomo, Inc. (MYO)	40.9	B/C	fortress balance sheet
153	Lifevantage Corp. (LFVN)	41.2	B/C	
154	Xeris Biopharma Holdings, Inc. (XERS)	41.5	B/C	
155	Envista Holdings Corp. (NVST)	41.7	B/C	
156	Sight Sciences, Inc. (SGHT)	42.0	B/C	fortress balance sheet
157	Repligen Corp. (RGEN)	42.3	B/C	late filer, fortress balance sheet
158	Community Health Systems Inc. (CYH)	42.5	C	
159	Ligand Pharmaceuticals Inc. (LGND)	42.8	C	
160	Nephros Inc. (NEPH)	43.1	C	fortress balance sheet

What the price implies

at the 2026-10-23 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	33.2%	7.7%	68
Distance from 52-week high	(22.0%)	(31.4%)	61
EBIT to enterprise value	5.3%	(1.5%)	81
Free cash flow yield	6.1%	(1.0%)	86
Book value to price	0.81	0.28	80
Sales to price	0.72	0.30	76
Composite equity issuance, five years	0.3%	20.5%	27

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Relative strength against the sector, log excess return	0.07	(0.14)	68

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 7 of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	pass
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$1.1B
Operating cash flow, four quarters	$302.6M
Months of runway	not finite
Days since last periodic filing	81 (10-Q received Aug 5, 2026)
Median daily dollar volume, 63 sessions	$65.3M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$1.5B	2025-12-31	2026-02-12	10-K	26-000011
2	assets	us-gaap:Assets	$5.7B	2025-12-31	2026-02-12	10-K	26-000011
3	operating income	us-gaap:OperatingIncomeLoss	$216.1M	2025-12-31	2026-02-12	10-K	26-000011
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$177.2M	2025-12-31	2026-02-12	10-K	26-000011
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$130.2M	2025-12-31	2026-02-12	10-K	26-000011
6	total debt	us-gaap:LongTermDebt	$1.4B	2025-12-31	2026-02-12	10-K	26-000011
7	book equity	us-gaap:StockholdersEquity	$3.1B	2025-12-31	2026-02-12	10-K	26-000011
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$1.2B	2025-12-31	2026-02-12	10-K	26-000011
9	total debt	us-gaap:LongTermDebt	$1.4B	2024-12-31	2026-02-12	10-K	26-000011
10	book equity	us-gaap:StockholdersEquity	$2.9B	2024-12-31	2026-02-12	10-K	26-000011
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$1.1B	2024-12-31	2026-02-12	10-K	26-000011
12	net income	us-gaap:NetIncomeLoss	$47.0M	2025-12-31	2026-02-12	10-K	26-000011
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$275.7M	2025-12-31	2026-02-12	10-K	26-000011
14	assets	us-gaap:Assets	$5.4B	2024-12-31	2026-02-12	10-K	26-000011
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$2.7B	2025-12-31	2026-02-12	10-K	26-000011
16	gross profit	us-gaap:GrossProfit	$1.4B	2024-12-31	2026-02-12	10-K	26-000011
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$2.5B	2024-12-31	2026-02-12	10-K	26-000011
18	gross profit	us-gaap:GrossProfit	$1.4B	2023-12-31	2026-02-12	10-K	26-000011
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$2.6B	2023-12-31	2026-02-12	10-K	26-000011
20	gross profit	us-gaap:GrossProfit	$1.5B	2022-12-31	2025-02-13	10-K	25-000007
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$2.6B	2022-12-31	2025-02-13	10-K	25-000007
22	gross profit	us-gaap:GrossProfit	$1.4B	2021-12-31	2024-02-15	10-K	24-000019
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$2.5B	2021-12-31	2024-02-15	10-K	24-000019
24	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$116.0M	2025-12-31	2026-02-12	10-K	26-000011
25	operating income	us-gaap:OperatingIncomeLoss	$31.5M	2023-12-31	2026-02-12	10-K	26-000011
26	interest expense	us-gaap:InterestExpense	$63.4M	2023-12-31	2024-02-15	10-K	24-000019
27	current assets	us-gaap:AssetsCurrent	$2.0B	2025-12-31	2026-02-12	10-K	26-000011
28	current liabilities	us-gaap:LiabilitiesCurrent	$852.6M	2025-12-31	2026-02-12	10-K	26-000011
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$45.3M	2025-12-31	2026-02-12	10-K	26-000011
30	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$336.5M	2024-12-31	2026-02-12	10-K	26-000011

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$33.8M	2024-12-31	2026-02-12	10-K	26-000011
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$275.7M	2023-12-31	2026-02-12	10-K	26-000011
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$58.2M	2023-12-31	2026-02-12	10-K	26-000011
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$182.7M	2022-12-31	2025-02-13	10-K	25-000007
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$75.7M	2022-12-31	2025-02-13	10-K	25-000007
36	current assets	us-gaap:AssetsCurrent	$1.8B	2024-12-31	2026-02-12	10-K	26-000011
37	current liabilities	us-gaap:LiabilitiesCurrent	$878.7M	2024-12-31	2026-02-12	10-K	26-000011
38	assets	us-gaap:Assets	$6.6B	2023-12-31	2025-02-13	10-K	25-000007
39	assets	us-gaap:Assets	$6.6B	2022-12-31	2024-02-15	10-K	24-000019
40	shares outstanding	dei:EntityCommonStockSharesOutstanding	163,875,397	2026-02-06	2026-02-12	10-K	26-000011
41	shares outstanding	dei:EntityCommonStockSharesOutstanding	172,188,060	2025-02-07	2025-02-13	10-K	25-000007

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.